nach oben

Erschienen in:

31.10.2018 | Original Article

Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants

verfasst von: Christopher Beynon, Steffen Brenner, Alexander Younsi, Timolaos Rizos, Jan-Oliver Neumann, Johannes Pfaff, Andreas W. Unterberg

Erschienen in: Neurocritical Care | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Anticoagulation therapy is a major risk factor for unfavorable patient outcomes following (traumatic) intracranial hemorrhage. Direct oral anticoagulants (DOAC) are increasingly used for the prevention and treatment of thromboembolic diseases. Data on patients treated for acute subdural hemorrhage (SDH) during anticoagulation therapy with DOAC are limited.

Methods

We analyzed the medical records of consecutive patients treated at our institution for acute SDH during anticoagulation therapy with DOAC or vitamin K antagonists (VKA) during a period of 30 months. Patient characteristics such as results of imaging and laboratory studies, treatment modalities and short-term patient outcomes were included.

Results

A total of 128 patients with preadmission DOAC (n = 65) or VKA (n = 63) intake were compared. The overall 30-day mortality rate of this patient cohort was 27%, and it did not differ between patients with DOAC or VKA intake (26% vs. 27%; p = 1.000). Similarly, the rates of neurosurgical intervention (65%) and intracranial re-hemorrhage (18%) were comparable. Prothrombin complex concentrates were administered more frequently in patients with VKA intake than in patients with DOAC intake (90% vs. 58%; p < 0.0001). DOAC treatment in patients with acute SDH did not increase in-hospital and 30-day mortality rates compared to VKA treatment.

Conclusions

These findings support the favorable safety profile of DOAC in patients, even in the setting of intracranial hemorrhage. However, the availability of specific antidotes to DOAC may further improve the management of these patients.

Karni A, Holtzman R, Bass T, Zorman G, Carter L, Rodriguez L, et al. Traumatic head injury in the anticoagulated elderly patient: a lethal combination. Am Surg. 2001;67:1098–100.PubMed

Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6–46.CrossRefPubMed

Becattini C, Franco L, Beyer-Westendorf J, Masotti L, Nitti C, Vanni S, et al. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol. 2017;227:261–6.CrossRefPubMed

Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology. 2017;88:1693–700.CrossRefPubMedPubMedCentral

Purrucker JC, Haas K, Rizos T, Khan S, Wolf M, Hennerici MG, et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol. 2016;73:169–77.CrossRefPubMed

von der Brelie C, Doukas A, Naumann R, Dempfle A, Larsen N, Synowitz M, et al. Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitamin K anticoagulants. Acta Neurochir (Wien). 2017;159:101–9.CrossRef

Beynon C, Sakowitz OW, Störzinger D, Orakcioglu B, Radbruch A, Potzy A, et al. Intracranial haemorrhage in patients treated with direct oral anticoagulants. Thromb Res. 2015;136:560–5.CrossRefPubMed

Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902.CrossRefPubMed

Bershad EM, Farhadi S, Suri MFK, Feen ES, Hernandez OH, Selman WR, et al. Coagulopathy and inhospital deaths in patients with acute subdural hematoma. J Neurosurg. 2008;109:664–9.CrossRefPubMed

10.

Mina AA, Knipfer JF, Park DY, Bair HA, Howells GA, Bendick PJ. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J Trauma. 2002;53:668–72.CrossRefPubMed

11.

Lin L-M, Paff M, Xu R, Jiang B, Colby GP, Coon AL. Chronic anticoagulation with warfarin is associated with decreased functional outcome and increased length of stay following craniotomy for acute subdural hematoma. Interdiscip Neurosurg. 2017;8:35–9.CrossRef

12.

Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34:2094–106.CrossRefPubMed

13.

Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100.CrossRefPubMedPubMedCentral

14.

Boulouis G, Morotti A, Pasi M, Goldstein JN, Gurol ME, Charidimou A. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89:263–70.CrossRefPubMed

15.

Inohara T, Xian Y, Liang L, Matsouaka RA, Saver JL, Smith EE, et al. Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist versus vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA. 2018;319:463–73.CrossRefPubMedPubMedCentral

16.

Pozzessere A, Grotts J, Kaminski S. Dabigatran use does not increase intracranial hemorrhage in traumatic geriatric falls when compared with warfarin. Am Surg. 2015;81:1039–42.PubMed

17.

Batey M, Hecht J, Callahan C, Wahl W. Direct oral anticoagulants do not worsen traumatic brain injury after low-level falls in the elderly. Surgery. 2018;164:814–9.CrossRefPubMed

18.

Kobayashi L, Barmparas G, Bosarge P, Brown CV, Bukur M, Carrick MM, et al. Novel oral anticoagulants and trauma: the results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial. J Trauma Acute Care Surg. 2017;82:827–35.CrossRefPubMed

19.

Feeney JM, Santone E, DiFiori M, Kis L, Jayaraman V, Montgomery SC. Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: a TQIP study. J Trauma Acute Care Surg. 2016;81:843–8.CrossRefPubMed

20.

Prexl O, Bruckbauer M, Voelckel W, Grottke O, Ponschab M, Maegele M, et al. The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old. Scand J Trauma Resusc Emerg Med. 2018;26:20.CrossRefPubMedPubMedCentral

21.

Cipriano A, Pecori A, Bionda AE, Bardini M, Frassi F, Leoli F, et al. Intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: significant differences between direct oral anticoagulants and vitamin K antagonists. Intern Emerg Med. 2018;13:1077–87.CrossRefPubMed

22.

Parra MW, Zucker L, Johnson ES, Gullett D, Avila C, Wichner ZA, et al. Dabigatran bleed risk with closed head injuries: are we prepared? J Neurosurg. 2013;119:760–5.CrossRefPubMed

23.

Beynon C, Potzy A, Sakowitz O, Unterberg AW. Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: a dangerous combination? Clin Neurol Neurosurg. 2015;136:73–8.CrossRefPubMed

24.

Senger S, Keiner D, Hendrix P, Oertel J. New target-specific oral anticoagulants and intracranial bleeding: management and outcome in a single-center case series. World Neurosurg. 2016;88:132–9.CrossRefPubMed

25.

Zeeshan M, Jehan F, O’Keeffe T, Khan M, Zakaria ER, Hamidi M, et al. The novel oral anticoagulants (NOACs) have worse outcomes compared to warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg. 2018. https://doi.org/10.1097/TA.0000000000001995.CrossRefPubMed

26.

Huang KT, Bi WL, Abd-El-Barr M, Yan SC, Tafel IJ, Dunn IF, et al. The neurocritical and neurosurgical care of subdural hematomas. Neurocrit Care. 2016;24:294–307.CrossRefPubMed

27.

Poulsen FR, Halle B, Pottegård A, García Rodríguez LA, Hallas J, Gaist D. Subdural hematoma cases identified through a Danish patient register: diagnosis validity, clinical characteristics, and preadmission antithrombotic drug use. Pharmacoepidemiol Drug Saf. 2016;25:1253–62.CrossRefPubMed

28.

Gaist D, García Rodríguez LA, Hellfritzsch M, Poulsen FR, Halle B, Hallas J, et al. Association of antithrombotic drug use with subdural hematoma risk. JAMA. 2017;317:836–46.CrossRefPubMed

29.

Connolly BJ, Pearce LA, Hart RG. Vitamin K antagonists and risk of subdural hematoma: meta-analysis of randomized clinical trials. Stroke. 2014;45:1672–8.CrossRefPubMed

30.

Hart RG, Diener H-C, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43:1511–7.CrossRef

31.

Hankey GJ, Stevens SR, Piccini JP, Lokhnygina Y, Mahaffey KW, Halperin JL, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45:1304–12.CrossRef

32.

Won S-Y, Dubinski D, Bruder M, Cattani A, Seifert V, Konczalla J. Acute subdural hematoma in patients on oral anticoagulant therapy: management and outcome. Neurosurg Focus. 2017;43:E12.CrossRefPubMed

33.

Sandén P, Renlund H, Svensson PJ, Själander A. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR. Thromb Haemost. 2017;117:27–32.CrossRefPubMed

34.

Douxfils J, Ageno W, Samama C-M, Lessire S, Ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16:209–19.CrossRefPubMed

35.

Beynon C, Wessels L, Unterberg AW. Point-of-care testing in neurosurgery. Semin Thromb Hemost. 2017;43:416–22.CrossRefPubMed

36.

Henskens YMC, Gulpen AJW, van Oerle R, Wetzels R, Verhezen P, Spronk H, et al. Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation. Thromb J. 2018;16:3.CrossRefPubMedPubMedCentral

37.

Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206–32.CrossRefPubMedPubMedCentral

38.

Martin A-C, Le Bonniec B, Fischer A-M, Marchand-Leroux C, Gaussem P, Samama C-M, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168:4228–33.CrossRefPubMed

39.

Herzog E, Kaspereit F, Krege W, Mueller-Cohrs J, Doerr B, Niebl P, et al. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. J Thromb Haemost. 2015;13:2220–6.CrossRefPubMedPubMedCentral

40.

Gerner ST, Kuramatsu JB, Sembill JA, Sprügel MI, Endres M, Haeusler KG, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018;83:186–96.CrossRefPubMed

41.

Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–36.CrossRefPubMed

42.

Laible M, Jenetzky E, Beynon C, Müller OJ, Sander P, Schüler S, et al. Adverse events following international normalized ratio reversal in intracerebral hemorrhage. Cerebrovasc Dis. 2016;42:446–54.CrossRefPubMed

43.

Yanamadala V, Walcott BP, Fecci PE, Rozman P, Kumar JI, Nahed BV, et al. Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage. J Clin Neurosci. 2014;21:1881–4.CrossRefPubMedPubMedCentral

44.

Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011;106:429–38.CrossRefPubMed

45.

Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.CrossRefPubMed

46.

Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41.CrossRefPubMedPubMedCentral

47.

Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet. 2016;387:2605–13.CrossRefPubMed

Titel: Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants
verfasst von: Christopher Beynon
Steffen Brenner
Alexander Younsi
Timolaos Rizos
Jan-Oliver Neumann
Johannes Pfaff
Andreas W. Unterberg
Publikationsdatum: 31.10.2018
Verlag: Springer US
Erschienen in: Neurocritical Care / Ausgabe 2/2019
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-018-0635-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Association Between Therapeutic Hypothermia and Outcomes in Patients with Non-shockable Out-of-Hospital Cardiac Arrest Developed After Emergency Medical Service Arrival (SOS-KANTO 2012 Analysis Report)

Author’s Response to Letter to the Editor: Noninvasive Intracranial Pressure Assessment in Acute Liver Failure

Characterizing the Response to Cerebrospinal Fluid Drainage in Patients with an External Ventricular Drain: The Pressure Equalization Ratio

Stroke and Craniectomy

Temporal Dynamics of Cerebral Blood Flow During the Acute Course of Severe Subarachnoid Hemorrhage Studied by Bedside Xenon-Enhanced CT